Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Sep 4;113(9):1127-1128.
doi: 10.1093/jnci/djab037.

BRCA1/2 and Endometrial Cancer Risk: Implications for Management

Mark E Sherman  1 , William D Foulkes  2
Affiliations
Editorial

BRCA1/2 and Endometrial Cancer Risk: Implications for Management

Mark E Sherman et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Comment on

  • Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
    de Jonge MM, de Kroon CD, Jenner DJ, Oosting J, de Hullu JA, Mourits MJE, Gómez Garcia EB, Ausems MGEM, Margriet Collée J, van Engelen K, van de Beek I; Hebon Group; Smit VTHBM, Rookus MA, de Bock GH, van Leeuwen FE, Bosse T, Dekkers OM, van Asperen CJ. de Jonge MM, et al. J Natl Cancer Inst. 2021 Sep 4;113(9):1203-1211. doi: 10.1093/jnci/djab036. J Natl Cancer Inst. 2021. PMID: 33710348 Free PMC article.

References

    1. de Jonge MM, de Kroon CD, Jenner DJ, et al. Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations: multi-center cohort study. J Natl Cancer Inst. 2021;113(9):1203–1211. - PMC - PubMed
    1. LaDuca H, Polley EC, Yussuf A, et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med. 2020;22(2):407–415. - PMC - PubMed
    1. Saule C, Mouret-Fourme E, Briaux A, et al. Risk of serous endometrial carcinoma in women with pathogenic BRCA1/2 variant after risk-reducing salpingo-oophorectomy. J Natl Cancer Inst. 2018;110(2):213–215. - PubMed
    1. Shu CA, Pike MC, Jotwani AR, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016;2(11):1434–1440. - PMC - PubMed
    1. Nahshon C, Segev Y, Gemer O, et al. Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients–a systematic review and meta-analysis. Gynecol Oncol. 2021;160(3):755–762. - PubMed